

## MYELOID NEOPLASIA

## Comprehensive mutational profiling of core binding factor acute myeloid leukemia

Nicolas Duployez,<sup>1,2</sup> Alice Marceau-Renaut,<sup>1,2</sup> Nicolas Boissel,<sup>3</sup> Arnaud Petit,<sup>4</sup> Maxime Bucci,<sup>1</sup> Sandrine Geffroy,<sup>1,2</sup> H el ene Lapillonne,<sup>5</sup> Aline Renneville,<sup>1,2</sup> Christine Ragu,<sup>4</sup> Martin Figeac,<sup>6</sup> Karine Celli-Lebras,<sup>3</sup> Catherine Lacombe,<sup>7</sup> Jean-Baptiste Micol,<sup>8,9</sup> Omar Abdel-Wahab,<sup>9</sup> Pascale Cornillet,<sup>10</sup> Norbert Ifrah,<sup>11</sup> Herv e Dombret,<sup>3</sup> Guy Leverger,<sup>4</sup> Eric Jourdan,<sup>12</sup> and Claude Preudhomme<sup>1,2</sup>

<sup>1</sup>Biology and Pathology Center, Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France; <sup>2</sup>Cancer Research Institute, INSERM Unit  Mixte de Recherche (UMR)–S 1172, Lille, France; <sup>3</sup>Department of Hematology, Saint Louis Hospital, Assistance Publique–H opitaux de Paris (AP-HP), Paris, France; <sup>4</sup>Department of Pediatric Hematology and Oncology, Trousseau Hospital, AP-HP, Paris, France; <sup>5</sup>Laboratory of Hematology, Trousseau Hospital, AP-HP, Paris, France; <sup>6</sup>Functional and Structural Genomic Platform, Lille University, Lille, France; <sup>7</sup>Goelamsth eque, Cochin Hospital, AP-HP, Paris, France; <sup>8</sup>Department of Hematology, Gustave Roussy Institute, INSERM UMR 1170, Villejuif, France; <sup>9</sup>Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; <sup>10</sup>Laboratory of Hematology, CHU Reims, Reims, France; <sup>11</sup>Department of Hematology, CHU Angers, Angers, France; and <sup>12</sup>Department of Hematology, CHU Nimes, Nimes, France

## Key Points

- Recurrent mutations in chromatin modifiers and cohesin were observed in t(8;21) AML, but not inv(16) AML.
- t(8;21) AML patients with mutations in kinase signaling plus chromatin modifiers or cohesin members had the highest risk of relapse.

Acute myeloid leukemia (AML) with t(8;21) or inv(16) have been recognized as unique entities within AML and are usually reported together as core binding factor AML (CBF-AML). However, there is considerable clinical and biological heterogeneity within this group of diseases, and relapse incidence reaches up to 40%. Moreover, translocations involving CBFs are not sufficient to induce AML on its own and the full spectrum of mutations coexisting with CBF translocations has not been elucidated. To address these issues, we performed extensive mutational analysis by high-throughput sequencing in 215 patients with CBF-AML enrolled in the Phase 3 Trial of Systematic Versus Response-adapted Timed-Sequential Induction in Patients With Core Binding Factor Acute Myeloid Leukemia and Treating Patients with Childhood Acute Myeloid Leukemia with Interleukin-2 trials (age, 1-60 years). Mutations in genes activating tyrosine kinase signaling (including *KIT*, *N/KRAS*, and *FLT3*) were frequent in both subtypes of CBF-AML. In contrast, mutations in genes that regulate chromatin conformation or encode members of the cohesin complex were observed with high frequencies in t(8;21) AML (42%

and 18%, respectively), whereas they were nearly absent in inv(16) AML. High *KIT* mutant allele ratios defined a group of t(8;21) AML patients with poor prognosis, whereas high *N/KRAS* mutant allele ratios were associated with the lack of *KIT* or *FLT3* mutations and a favorable outcome. In addition, mutations in epigenetic modifying or cohesin genes were associated with a poor prognosis in patients with tyrosine kinase pathway mutations, suggesting synergic cooperation between these events. These data suggest that diverse cooperating mutations may influence CBF-AML pathophysiology as well as clinical behavior and point to potential unique pathogenesis of t(8;21) vs inv(16) AML. (*Blood*. 2016;127(20):2451-2459)

## Introduction

Core binding factor (CBF) acute myeloid leukemia (AML) includes AML with t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22) chromosomal rearrangements (abbreviated as t(8;21) as inv(16), respectively), leading to the *RUNX1-RUNX1T1* and *CBFB-MYH11* fusion genes, respectively. CBF AML is among the most common cytogenetic subtypes of AML because t(8;21) and inv(16) together account for approximately 25% of pediatric and 15% of adult de novo AML patients.<sup>1</sup> Their identification is critical in routine practice because the presence of these alterations significantly affects clinical management of AML.<sup>2</sup> CBF AML is considered to have a good prognosis relative to other AML subtypes, and treatments using high-dose

cytarabine-based chemotherapy have resulted in markedly improved outcome. Nonetheless, relapse occurs up to 40% in such patients, indicating clinical heterogeneity among CBF AML patients.<sup>3-6</sup>

Since the first description of t(8;21) and inv(16) AML in 1973<sup>7</sup> and 1983,<sup>8</sup> respectively, a great deal has been learned about the molecular consequences of both rearrangements. Both alterations result in disruption of genes encoding subunits of the CBF complex (ie, *RUNX1* and *CBFB*), a heterodimeric transcription factor complex that regulates the expression of genes required for normal hematopoiesis.<sup>9,10</sup> Homozygous disruption of *Runx1* or *Chfb* in mice results in identical developmental defects, including failure to

Submitted December 23, 2015; accepted March 8, 2016. Prepublished online as *Blood* First Edition paper, March 15, 2016; DOI 10.1182/blood-2015-12-688705.

The online version of this article contains a data supplement.

There is an Inside *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

  2016 by The American Society of Hematology

develop definitive hematopoiesis and embryonic death.<sup>11</sup> At the same time, experience from murine models has demonstrated that the expression of the *RUNX1-RUNX1T1* or *CBFB-MYH11* fusion proteins alone induces aberrant self-renewal, but is insufficient to induce fulminant leukemia.<sup>11</sup> Consistent with this, preleukemic cells harboring *RUNX1-RUNX1T1* or *CBFB-MYH11* fusion genes were identified >10 years before clinical development of AML as well as following long-term clinical remission of AML.<sup>12,13</sup> CBF AML is therefore considered a model for the multistep pathogenesis of leukemia, in which AML development requires cooperation from disruption of a transcription factor (such as the CBF complex) that impairs differentiation, plus activating mutations that increase proliferation (the “2-hit model” of leukemogenesis).<sup>14</sup> Further evidence supporting this model comes from the fact that frequent mutations activating tyrosine kinase (TK) signaling (including *KIT*, *FLT3*, and *NKRS* family genes) are frequently observed in both CBF AML subtypes.<sup>3</sup>

Given the similarities in prognostic features and involvement of CBF transcription factors in their pathogenesis, t(8;21) and inv(16) AML have been recognized as unique entities within AML and are usually grouped and reported together in clinical studies. However, patients with t(8;21) or inv(16) AML differ with respect to several biological and clinical features.<sup>15</sup> Morphologically, patients with t(8;21) AML frequently present with the French-American-British morphological subtype M2 or AML with maturation, whereas patients with inv(16) more often are diagnosed with the French-American-British subtype M4Eo or acute myelomonocytic leukemia with abnormal marrow eosinophils.<sup>16</sup> Moreover, gene expression profiling of CBF AML segregate t(8;21) and inv(16) patients into distinct subgroups,<sup>17</sup> reflecting different pathways activated in each subtype of CBF AML.<sup>18</sup> Although a genetic basis for morphologic and transcriptional differences between t(8;21) and inv(16) AML were previously unknown, frequent mutations in *ASXL1* and *ASXL2* were recently described specifically in t(8;21) AML patients. *ASXL1/2* mutations have been described in ~35% of t(8;21) AML but are absent in inv(16)AML.<sup>19,20</sup> Interestingly, *ASXL2* mutations are not recurrent in subsets of AML other than t(8;21) AML, suggesting an important potential functional intersection between *ASXL2* mutations and the *RUNX1-RUNX1T1* fusion specifically.<sup>21</sup> Besides *ASXL1/2* mutations, however, no other recurrent mutations specific to 1 or both CBF AML subsets are currently known.

Given that (1) up to 40% of patients with CBF AML relapse and that (2) CBF disruption is not sufficient to induce AML on its own, we hypothesized that additional recurrent genetic abnormalities may be enriched in 1 or more subsets of CBF AML patients. Through extensive mutational analysis of a large and well-annotated cohort of CBF AML patients, we identified a series of recurrent genetic alterations in genes encoding epigenetic modifiers and cohesin members with direct relevance specifically in t(8;21) AML. Moreover, we identified additional importance of allelic ratios of mutations affecting TK signaling across CBF AML. These data suggest that t(8;21) and inv(16) AML may have distinct pathophysiology and that comprehensive genetic analysis may be used to refine prognostication in CBF AML.

## Methods

### Patients and treatments

This study included 215 patients with CBF AML, including 106 with t(8;21) and 109 with inv(16) AML. The cohort included 142 adults treated in the Phase 3 Trial of Systematic Versus Response-adapted Timed-Sequential Induction in Patients With Core Binding Factor Acute Myeloid Leukemia (CBF2006) trial<sup>3</sup>

(EudraCT 2006 005163-26; ClinicalTrials.gov NCT00428558) as well as 73 children treated in the Treating Patients with Childhood Acute Myeloid Leukemia with Interleukin-2 (ELAM02) trial (ClinicalTrials.gov NCT00149162) (supplemental Figure 1, available on the *Blood* Web site). Studies were approved by the Ethics Committee of Nimes University Hospital and by the Institutional Review Board of the French Regulatory Agency and were conducted in accordance with the Declaration of Helsinki protocol.

### Mutational analysis by high-throughput sequencing

Bone marrow samples from CBF AML patients at diagnosis were studied by high-throughput sequencing (HTS) of 40 genes recurrently mutated in myeloid malignancies. This included genes encoding proteins involved in signal transduction (*CBL* [exons 8-9], *CSF3R* [exons 3-18], *FLT3* [exons 14-15 + 20], *JAK2* [exons 12 + 14], *KIT* [exons 8-13 + 17], *KRAS* [exons 2-3], *MPL* [exon 10], *NRAS* [exons 2-3], *PTPN11* [exons 3 + 13]), transcription (*BCOR* [exons 2-15], *BCORL1* [exons 1-12], *CEBPA* [exon 1], *ETV6* [exons 1-8], *GATA1* [exon 2], *GATA2* [exons 2-6], *IKZF1* [exons 1-8] *RUNX1* [exons 1-6]), chromatin modification (*ASXL1* [exon 12], *ASXL2* [exons 1-12], *EZH2* [exons 2-20], *KDM6A* [exons 1-29], *KMT2A* [exons 5-8]), DNA methylation (*DNMT3A* [exons 2-23], *IDH1* [exon 4], *IDH2* [exon 4], *TET2* [exons 3-11]), RNA splicing (*SF3B1* [exons 13-18], *SRSF2* [exon 1], *U2AF1* [exons 2 + 6], *ZRSR2* [exons 1-11]), cohesin complex (*RAD21* [exons 2-14], *SMC1A* [exons 1-25], *SMC3* [exons 1-29], *STAG2* [exons 3-35]), tumor suppression (*PHF6* [exons 2-10], *TP53* [exons 2-11], *WT1* [exons 7 + 9]) and other pathways [*CALR* [exon 9], *NPM1* [exon 11], *SETBP1* [exon 4]]. For all but *ASXL2*, libraries were prepared using Haloplex Target Enrichment System (Agilent Technologies) according to the manufacturer's instructions and run on MiSeq (Illumina). A high depth of coverage (>2000×) was obtained for all genes (supplemental Figure 2), allowing detection of mutations with a variant allele frequency (VAF) until 1%. Raw HTS data were analyzed with 2 distinct softwares: SureCall (Agilent Technologies) and SeqNext (JSI Medical System). Frameshift and nonsense variants were always considered as relevant mutations. Single nucleotide variants were retained in the absence of description into public databases of human polymorphisms, and effects on protein function were predicted with 6 established prediction tools: SIFT (Sorting Intolerant From Tolerant), PolyPhen-1, PolyPhen-2, Multivariate Analysis of Protein Polymorphism, Support Vector Machines based Predictor of human Deleterious Single Nucleotide Polymorphism, and SNAP (Screening for Non-Acceptable Polymorphisms).<sup>22</sup> All variants were validated with another HTS technology with library preparation using the Ampliseq System and sequencing on a Personal Genome Machine (PGM, Life Technologies). Data from PGM sequencing were processed by Torrent Browser (Life Technologies) and SeqNext (JSI Medical System). *ASXL2* sequencing was performed as previously described.<sup>19</sup> Notably, because of technical limitations, the mutation c.1934dupG in *ASXL1* cannot be detected with PGM sequencing, justifying its systematic validation by Sanger sequencing as previously described.<sup>19</sup> In 1 case, this *ASXL1* variant could not be verified by Sanger sequencing because of a low VAF (4%), but was retained by visual check of the reads (UPN 53).

### Other cytogenetic and molecular analyses

The presence of the t(8;21) or the inv(16)/t(16;16) rearrangements were determined by karyotype (as well as additional cytogenetic abnormalities) and/or fluorescence in situ hybridization and/or evidence of *RUNX1-RUNX1T1* or *CBFB-MYH11* fusion transcripts, as previously described.<sup>3</sup> The presence of the *FLT3*-internal tandem duplication (ITD) was not determined by HTS, but systematic screening was performed for all patients, as previously described.<sup>23</sup> Minimal residual disease was evaluated with *RUNX1-RUNX1T1* or *CBFB-MYH11* real-time quantitative polymerase chain reaction analysis, as previously described.<sup>3</sup>

### Statistical methods

Failure time data were analyzed and compared after censoring at transplant for patients who received allogeneic stem cell transplantation (SCT) in first complete remission (CR). Cumulative incidence of relapse (CIR) and overall survival (OS) were estimated by the Kaplan-Meier method. CIR was estimated taking into account death in first CR for competing risk. CIR and OS were compared by cause-specific hazard Cox models after stratification on the trial (CBF2006 vs

ELAM02). Comparisons between patient subgroups were performed by the Mann-Whitney test for continuous variables and by Fisher's exact test for categorical variables. Optimal cut-points for allelic ratios were determined by maximally selected log-rank statistics.<sup>24</sup> Specific hazards of relapse (SHRs) and HRs are given with 95% confidence interval (CI). Univariate and multivariate analysis assessing the impact of categorical and continuous variables were performed with a Cox model. Proportional-hazards assumption was checked before conducting multivariate analyses.<sup>25</sup> Covariates with a *P* value < .1 in univariate analysis were included in the multivariable models. All statistical tests were performed with the Stata/IC 12.1 software (StataCorp, College Station, TX).

## Results

### Patients' characteristics at diagnosis

Patients' characteristics as well as additional molecular and cytogenetic aberrations are shown in Table 1 according to CBF subtype. Median age was 32 years (patients were aged from 1 to 17 years in the ELAM02 trial and from 18 to 60 years in the CBF2006 trial). The median follow-up was 5.3 years. Adult and pediatric patients were grouped together for further investigations because CIR was similar regardless of the trial (supplemental Figure 3). Patients with inv(16) AML were younger (median age, 25 vs 37; *P* = .004) and had a higher white blood cell (WBC) count (median, 34.4 vs 11.5; *P* < .001) than those with t(8;21) AML.

### Additional aberrations are found in >90% of CBF AML

Mutation frequencies are reported in Table 1. All identified variants with their VAFs are reported in supplemental Table 1. Among the 215 patients analyzed, 182 (85%) had at least 1 mutation. Among them, 72 patients had 1 alteration, 51 had 2, 41 had 3, 13 had 4, 4 had 5, and 1 had 6. Considering the most common cytogenetic abnormalities in CBF AML together with mutations, additional aberrations were found in 93% of CBF AML (96% and 90% of t(8;21) AML and inv(16) AML, respectively). Figure 1 depicts the identified mutations as well as additional cytogenetic aberrations according to CBF AML subtype.<sup>26</sup> Notably, mutational patterns appeared to be quite similar regardless of age group (supplemental Table 2).

### Mutations disrupting tyrosine kinase signaling are the most frequent events in CBF AML

Among all genes sequenced, the most common mutations involved genes affecting TK signaling (especially *KIT*, *FLT3*, and *N/KRAS* mutations). A higher mutation incidence in these genes was identified here compared with prior studies using standard polymerase chain reaction and direct sequencing,<sup>3,23,27</sup> likely because HTS and cross-validation allowed for detection of mutations with very low VAFs (supplemental Figure 4).

*KIT* mutations were found in 40% of AML with t(8;21) and 33% of AML with inv(16) (*P* = .345). Most *KIT* mutations were small deletions and or insertions in exon 8, leading to replacement of codon D419 or point mutations in exon 17. All but 1 exon 17 mutation involved codons D816 and N822 in the activation loop of the kinase domain. *KIT* exon 11 mutations were only detected in 2 patients. Two patients harbored rare *KIT* variants K509I in exon 9 (UPN206) and N655K in exon 13 (UPN3), previously reported in pediatric mastocytosis<sup>28</sup> and gastrointestinal stromal tumor,<sup>29</sup> respectively, and demonstrated to cause constitutive ligand-independent activation of *KIT* (supplemental Figure 5A).

*FLT3*-TKD mutations (especially at codon D835) were involved in 22% of inv(16) AML, but only 4% of t(8;21) AML (*P* < .001). On the other hand, *FLT3*-ITD was present in only 3% of inv(16) AML, whereas they occurred in 10% of t(8;21) AML (*P* = .028).

Notably, adult and pediatric patients with inv(16) AML differ by the pattern of mutations in genes coding for receptor tyrosine kinases (RTK) *KIT* and *FLT3*, a feature not shared by t(8;21) AML patients. Indeed, *FLT3*-TKD mutations have an incidence of 28% in adult inv(16) AML, whereas they account for 7% of pediatric cases (*P* = .019). On the other hand, *KIT* mutations are found in 50% of pediatric inv(16) AML cases, but were present in 27% of adult cases (*P* = .024) (supplemental Figure 6).

As previously reported,<sup>30</sup> *RAS* (*NRAS* or *KRAS*) mutations were the most frequent mutations in inv(16) AML. *RAS* mutations were found in 54% of inv(16) AML and 26% of t(8;21) AML (*P* < .001). All but 4 *RAS* mutations involved the hotspots at codons G12, G13, and Q61 (supplemental Figure 5B).

Other events in TK pathway included rare mutations in *JAK2* (V617F) *CBL* and *PTPN11*.

### Cooccurring mutations in TK pathway gene members are frequent in CBF-AML

Seventy-five CBF AML patients (35%) had 2 or more mutations in genes coding for TK pathway effectors (involving the same gene or different genes, especially *KIT*, *FLT3*, and *RAS* genes). Among them, 6 patients had 2 or more *KIT* mutations, 25 patients had 2 or more *RAS* mutations, and 8 patients had 2 or more *FLT3*-ITD or TKD mutations. These findings highlight the multiclonality of CBF AML (supplemental Figure 7). In all but 6 CBF AML patients, the total of VAFs for TK pathway mutations was less than 50% (corresponding to 1 heterozygous mutation per cell). In the 6 remaining patients, 2 had mutations in the *CBL* gene, which is known to be involved in uniparental disomies,<sup>31</sup> and 1 patient (UPN 71) had a *KIT* mutation with a VAF at 62%. In this patient, review of the karyotype showed duplication of the long arm of the chromosome 4 (probably containing the mutated *KIT* gene). Considering the redundant effects of these mutations, it is likely they occur in distinct clones although further investigations are needed to study clonal architecture and extend those findings.

### Mutations of epigenetic regulators and cohesin complex are common in t(8;21) but rare in inv(16) CBF AML

Mutations in genes encoding epigenetic regulators that control chromatin conformation were found in 42% of t(8;21) AML cases, but only in 6% of inv(16) AML cases (*P* < .001). These mutations were largely mutually exclusive with 1 another (supplemental Figure 8). Among t(8;21) AML patients, *ASXL1* or *ASXL2* mutations occurred together in 32% of cases (all mutations were frameshift and nonsense mutations). *EZH2* mutations were identified in 7% of t(8;21) AML. All but 1 were located within the post-SET domain, normal expression of which is essential for the conformation of the protein and its subsequent catalytic activity.<sup>32</sup> Other alterations within chromatin modifiers included *KDM6A*, *BCOR*, and *BCORL1* mutations in 6%, 1%, and 3% of patients with t(8;21) AML.

Likewise, mutations in genes encoding members of the cohesin complex were identified specifically in patients in t(8;21) AML, but not in inv(16) AML. Cohesin mutations were present in 18% of t(8;21) AML, but in none of the inv(16) AML patients (*P* < .001). All cohesin mutations were mutually exclusive among each other (supplemental Figure 9). All *RAD21* and *STAG2* mutations were nonsense or out-of-frame frameshift mutations. *SMC1A* and *SMC3* mutations were missense mutations and involved functional domains (mostly hinge

**Table 1. Patient characteristics according to CBF subtype**

	CBF-AML	AML with inv(16)	AML with t(8;21)	P value
Patients, n	215	109	106	
Median age, y (range)	32 (1-60)	37 (1-60)	25 (2-59)	.004*
Median WBC, $\times 10^9/L$ (range)	18.4 (1-232)	34.4 (1-232)	11.5 (1.3-163)	<.001*
Gender (male/female)	119/96	61/48	58/48	.891
Trial (CBF2006/ELAM02)	142/73	79/30	63/43	.046*
<b>Outcome</b>				
Deaths, n (%)	35 (16)	15 (14)	20 (18)	.358
Relapses, n (%)	70 (33)	34 (31)	36 (33)	.771
Number of mutations per patient	2 (0-6)	1 (0-5)	2 (0-6)	.277
<b>Gene mutations</b>				
Tyrosine kinase pathway, n (%)	156 (73)	87 (80)	69 (65)	.021*
<i>KIT</i> exon 8, n (%)	37 (17)	22 (20)	15 (14)	.352
<i>KIT</i> exon 17, n (%)	42 (20)	16 (15)	26 (25)	.080
Codon D816 (exon 17), n (%)	30 (14)	13 (12)	17 (16)	.421
Codon N822 (exon 17), n (%)	12 (6)	2 (2)	10 (9)	.032*
<i>KIT</i> exon 11, nm(%)	2 (1)	1 (1)	1 (1)	1.000
<i>KIT</i> all, n (%)	78 (36)	36 (33)	42 (40)	.325
<i>FLT3-TKD</i> , n (%)	28 (13)	24 (22)	4 (4)	<.001*
<i>FLT3-ITD</i> , n (%)	14 (7)	3 (3)	11 (10)	.028*
<i>FLT3</i> all, n (%)	41 (19)	26 (24)	15 (14)	.083
RTK ( <i>KIT</i> and/or <i>FLT3</i> ), n (%)	105 (49)	53 (49)	52 (49)	1.000
<i>NRAS</i> , n (%)	66 (31)	42 (39)	24 (23)	.012*
Codon G12, n (%)	24 (11)	14 (13)	10 (9)	.518
Codon G13, n (%)	19 (9)	9 (8)	10 (9)	.813
Codon Q61, n (%)	34 (16)	26 (24)	8 (8)	.001*
<i>KRAS</i> , n (%)	36 (17)	29 (27)	7 (7)	<.001*
Codon G12, n (%)	15 (7)	14 (13)	1 (1)	<.001*
Codon G13, n (%)	13 (6)	8 (7)	5 (5)	.569
Codon Q61, n (%)	6 (3)	5 (5)	1 (1)	.212
<i>RAS</i> ( <i>NRAS</i> and/or <i>KRAS</i> ), n (%)	87 (40)	59 (54)	28 (26)	<.001*
<i>JAK2</i> , n (%)	3 (1)	0 (0)	3 (3)	.118
<i>PTPN11</i> , n (%)	8 (4)	5 (5)	3 (3)	.722
<i>CBL</i> , n (%)	2 (1)	0 (0)	2 (2)	.242
Chromatin modifiers, n (%)	51 (24)	6 (6)	45 (42)	<.001*
<i>ASXL1</i> , n (%)	11 (5)	0 (0)	11 (10)	<.001*
<i>ASXL2</i> , n (%)	23 (11)	0 (0)	23 (22)	<.001*
<i>ASXL</i> ( <i>ASXL1</i> or <i>ASXL2</i> ), n (%)	34 (16)	0 (0)	34 (32)	<.001*
<i>KDM6A</i> , n (%)	9 (4)	3 (3)	6 (6)	.328
<i>EZH2</i> , n (%)	7 (3)	0 (0)	7 (7)	.006*
<i>BCOR</i> , n (%)	2 (1)	1 (1)	1 (1)	1.000
<i>BCORL1</i> , n (%)	6 (3)	3 (3)	3 (3)	1.000
DNA methylation, n (%)	10 (5)	2 (2)	8 (8)	.057
<i>TET2</i> , n (%)	5 (2)	0 (0)	5 (5)	.028*
<i>IDH1</i> , n (%)	3 (1)	2 (2)	1 (1)	1.000
<i>IDH2</i> , n (%)	2 (1)	0 (0)	2 (2)	.242
Cohesin, n (%)	19 (9)	0 (0)	19 (18)	<.001*
<i>RAD21</i> , n (%)	8 (4)	0 (0)	8 (8)	.003*
<i>SMC1A</i> , n (%)	5 (2)	0 (0)	5 (5)	.028*
<i>SMC3</i> , n (%)	5 (2)	0 (0)	5 (5)	.028*
<i>STAG2</i> , n (%)	1 (0)	0 (0)	1 (1)	.493
Transcription factors, n (%)	6 (3)	1 (1)	5 (5)	.116
<i>ETV6</i> , n (%)	2 (1)	1 (1)	1 (1)	1.000
<i>RUNX1</i> , n (%)	1 (0)	0 (0)	1 (1)	.493
<i>GATA2</i> , n (%)	2 (1)	0 (0)	2 (2)	.242
<i>IKZF1</i> , n (%)	1 (0)	0 (0)	1 (1)	.493
Spliceosome, n (%)	2 (1)	1 (1)	1 (1)	1.000
<i>SRSF2</i> , n (%)	2 (1)	1 (1)	1 (1)	1.000
Tumor suppressors, n (%)	11 (5)	7 (6)	4 (4)	.538
<i>PHF6</i> , n (%)	1 (0)	0 (0)	1 (1)	.493
<i>WT1</i> , n (%)	11 (5)	7 (6)	4 (4)	.538

Adult and pediatric patients are reported together.

\* $P < .05$ .

**Table 1. (continued)**

	CBF-AML	AML with inv(16)	AML with t(8;21)	P value
<b>Additional cytogenetic abnormalities</b>				
Loss X or Y, n (%)	54 (25)	0 (0)	54 (51)	<.001*
Del(9q), n (%)	16 (7)	0 (0)	16 (15)	<.001*
Del(7q), n (%)	21 (10)	11 (10)	10 (9)	1.000
Trisomy 8, n (%)	18 (8)	12 (11)	6 (6)	.218
Trisomy 22, n (%)	12 (6)	12 (11)	0 (0)	<.001*

Adult and pediatric patients are reported together.  
\*P < .05.

domain and adenosine triphosphatase heads). Two patients harbored the same *SMC1A* variant R96H, previously reported in AML.<sup>33</sup> We found a hotspot in *SMC3* because 3 of 5 mutations involved the codon R661 in the hinge domain of the protein. Mutations involving this codon have been previously described in cancer as well as in the leukemia-derived cell line MOLM-7.<sup>34</sup>

Finally, mutations in effectors that control DNA methylation (*TET2*, *IDH1* R132H/L, or *IDH2* R140) were identified in 8% of t(8;21) AML cases and in 2% of inv(16) AML cases with mutual exclusivity (P = .57).

**Outcome**


The CR rate in this cohort of 215 patients was 98.1% (211/215). The 5-year CIR was 33.2% (95% CI, 27.2-40.2) with no difference between the CBF2006 and ELAM02 (35.2% [95% CI, 27.9-43.9] vs 29.3% [95% CI, 19.8-42.1], P = .415, supplemental Figure 3). The 5-years OS was 83.6% [95% CI, 77.7-88.0]. A total of 14 patients received allogeneic SCT in first CR and were censored at SCT time for prognostic analyses. Five-year CIR was estimated at 31% (95% CI, 23-41) in patients with inv(16) AML and 35% (95% CI, 27-46) in patients with t(8;21) AML. All but 1 patient, who died during induction course,

entered CR. Thirty-four patients died during follow-up: 9 died in first CR, 19 died after hematological relapse, and 6 adults died of allogeneic SCT complications. Seventy patients had hematological relapse.


**Importance of VAFs for evaluating impact of TK pathway mutations on outcome**

Univariate prognosis analyses for CIR are summarized in supplemental Table 3. Altogether, mutations in genes activating TK signaling were associated with a higher cumulative incidence of relapse (SHR, 2.81 [95% CI, 1.39-5.69]; P = .004) especially in t(8;21) AML patients (SHR, 5.22 [95% CI, 1.82-14.96]; P = .002). This was also evident across RTK mutations (*KIT* and/or *FLT3* mutations) (SHR, 1.72 [95% CI, 1.05-2.81]; P = .031).

Given the range in VAFs identified in mutations activating TK signaling, we determined optimal cut-points for VAFs in the most frequent mutations (ie, *KIT*, *FLT3*-TKD, *NRAS*, and *KRAS* mutations) by maximally selected log-rank statistics.<sup>24</sup> *KIT* mutations were associated with a significant higher CIR for t(8;21) AML patients with a mutant allelic ratio of 35% or greater (*KIT*<sup>≥35%</sup>). Patients in this particular subgroup had a particularly adverse outcome with a 5-year CIR of 69.4% vs 30.7% and 31.9% for *KIT*<sup><35%</sup> and *KIT*<sup>wildtype</sup>,



**Figure 1. Molecular alterations in CBF AML.** Each column represents the mutation pattern in 1 patient, and each colored box represents a mutation of the gene. Genes have been grouped in 7 categories according to reference.<sup>26</sup> Patients are grouped into AML with t(8;21) (left) and AML with inv(16) (right). Adult (CBF2006 trial, dark gray boxes) and pediatric patients (ELAM02, light gray boxes) are reported together.



**Figure 2. Kaplan-Meier curves for CIR in patients stratified according to their mutational profile.** Patients are separated in 3 groups: (1) TK pathway mutation associated with at least 1 mutation involving chromatin modifier or cohesin genes, (2) TK pathway mutation without mutations involving chromatin modifier or cohesin genes, and (3) other mutational profiles.

respectively ( $P = .008$ ) (supplemental Figure 10). In patients with  $t(8;21)$  and *KIT* mutation, the only baseline characteristic that was associated with a higher incidence of relapse was logWBC (SHR, 3.72 [95% CI, 0.97-14.28];  $P = .056$ ). In bivariate analysis, both logWBC and  $KIT^{\geq 35\%}$  remained significantly associated with a poorer prognosis (logWBC: SHR, 8.45 [95% CI, 1.93-36.90],  $P = .005$ ;  $KIT^{\geq 35\%}$ : SHR, 8.83 [95% CI, 2.45-31.76],  $P = .001$ ).

Similarly, *FLT3*-TKD mutations were associated with a higher CIR in CBF AML patients with a mutant allelic ratio of 10% or greater ( $FLT3$ -TKD $\geq 10\%$ ) when compared with lower ratio and nonmutated patients (SHR, 2.28 [95% CI, 1.16-4.50];  $P = .018$ ). The 5-year CIR was 58.8% (95% CI, 37.4-81.4) in patients with  $FLT3$ -TKD $\geq 10\%$ , 20.0% (95% CI, 5.4-59.1) in patients with  $FLT3$ -TKD $< 10\%$ , and 31.5% (95% CI, 25.2-39.0) in patients without *FLT3*-TKD. Conversely, high *NRAS* and *KRAS* mutant allelic ratios ( $> 35\%$ ) were both favorable factors for CIR in CBF AML (5-year CIR was 13% for  $NRAS^{\geq 35\%}$  vs 30.2% for  $NRAS^{wt}$  [ $P = .033$ ] and 0% for  $KRAS^{\geq 35\%}$  vs 31.9% for  $KRAS^{wt}$ , respectively [ $P = .008$ ]). Patients with high *NRAS* or *KRAS* mutant allelic ratios were characterized by the lack of RTK mutations, which could explain this favorable outcome (supplemental Figure 11).

#### Mutations in epigenetic modifying or cohesin genes are associated with a poor prognosis in $t(8;21)$ AML patients with TK pathway mutations

Besides mutations in genes affecting TK signaling, as previously reported, we observed a trend toward a higher SHR for *ASXL1/2* mutations (*ASXL1* or *ASXL2*) in patients with  $t(8;21)$  AML (SHR, 1.71 [95% CI, 0.88-3.33];  $P = .113$ ), which did not reach statistical

significance. Interestingly, in this CBF AML subtype, patients who had mutations in both TK pathways and chromatin modifiers and/or cohesin genes had the worst prognosis with a 5-year CIR of 54.1% (95% CI, 39.7-69.9) when compared with patients with TK mutations without chromatin modifiers and/or cohesin gene mutations (5-year CIR, 33.9% [95% CI, 25.8-43.8]), or to patients without TK mutations (5-year CIR, 16.3% [95% CI, 8.9-29.1]; Figure 2). In multivariate analysis (Table 2), the association of mutations in TK pathway genes and chromatin modifiers or cohesin genes remained associated with the highest hazard of relapse in patients with  $t(8;21)$  AML (SHR, 5.44 [95% CI, 1.82-16.27];  $P = .002$ ).

## Discussion

AML with  $t(8;21)$  and  $inv(16)$ , collectively referred to as CBF AML, represent 2 of the most common genetic abnormalities in AML. Both entities disrupt the normal function of the heterodimeric transcription factor CBF complex and have similar clinical outcomes. However, the molecular genetic abnormalities potentially explaining differences between these 2 subtypes of AML have not been explored in detail. Although implication of TK pathways in CBF AML leukemogenesis has been widely studied,<sup>15</sup> only a few reports have identified co-operating mutations in CBF AML outside of TK pathway alterations. Although the “2-hit model” of leukemogenesis mentioned earlier is biologically relevant, it is impossible to ignore the multitude of genetic and epigenetic aberrations that have recently been described in human leukemia.<sup>35</sup> Within CBF AML, *ASXL1* and *ASXL2* mutations were

**Table 2. Univariate and multivariate analyses for specific hazard of relapse in patients with t(8;21) AML**

	Patients	Univariate analysis			Multivariate analysis		
		SHR	95% CI	P value	SHR	95% CI	P value
Age*	106	1.00	0.97-1.03	.938	—	—	—
LogWBC*	106	2.47	1.18-5.19	.017†	1.94	0.89-4.27	.097
TK <sup>mut</sup> and (chromatin modifiers <sup>WT</sup> and cohesin <sup>WT</sup> )	31/106	3.88	1.20-12.54	.023†	3.96	1.22-12.91	.022†
TK <sup>mut</sup> and (chromatin modifiers <sup>mut</sup> and/or cohesin <sup>mut</sup> )	38/106	6.21	2.11-18.26	.001†	5.44	1.82-16.27	.002†

\*Tested as continuous variable.

†P &lt; .05.

recently reported to occur exclusively in AML with t(8;21), but not in AML with inv(16).<sup>19,20,36</sup> The present study extends those findings. We performed extensive mutational analysis by HTS in 215 patients with CBF AML from 1 to 60 years. As expected, mutations in TK pathways were the most frequent aberrations in both subtypes (65% and 80% of t(8;21) AML and inv(16) AML respectively; P = .021). Mutations in TK pathway, especially RTK mutations (*KIT* and *FLT3* mutations), were associated with a higher SHR and higher CIR. *KIT* mutations with high mutant allelic ratio appeared to significantly affect prognosis of t(8;21) AML patients in accordance with a previous report by Allen et al.<sup>37</sup> Conversely, high *NRAS* and *KRAS* mutant allelic ratios were associated with the lack of RTK mutations and a favorable outcome. *FLT3*-TKD mutations were associated with a higher CIR in the present study, especially in inv(16) AML. These results are in accordance with previous studies showing inferior OS and PFS in inv(16) AML,<sup>30,38</sup> although it remains controversial.<sup>39,40</sup>

However, TK pathways mutations appear to constitute only a portion of the genetic landscape of CBF AML. Interestingly, the 2 CBF AML subtypes showed greatly distinct mutational profiles. Mutations in genes that regulate chromatin conformation (*ASXL1/2*, *EZH2*, *KDM6A*, *BCOR/BCORL1*) or implicated in the cohesin complex (*RAD21*, *SMC1A*, *SMC3*, *STAG2*) were observed almost exclusively in t(8;21) AML. In line with those findings, using whole exome sequencing in 13 CBF AML patients, Sood et al recently identified cohesin and chromatin modifiers mutations in t(8;21) but not in inv(16) patients.<sup>41</sup>

Functionally, *ASXL1*, *ASXL2*, and *EZH2* are Polycomb group-associated proteins that influence chromatin configuration and thus gene transcription by directing modifications at specific chromatin marks. *EZH2* is the catalytic component of Polycomb Repressive Complex 2 (PRC2) and serves as a H3K27 methyltransferase activity. *ASXL1* and *ASXL2* are part of the Polycomb repressive deubiquitinase complex, which removes an ubiquitin from H2AK119 marks,<sup>42</sup> but studies have shown that *ASXL* proteins may also function in recruitment and/or stabilization of the PRC2 complex to specific loci.<sup>43</sup> *KDM6A* (also known as *UTX*) is an H3K27 demethylase that counters the enzymatic activity of PRC2. On the other hand, *BCOR* and *BCORL1* are part of a complex similar to the PRC1.<sup>44</sup>

Cohesin is a multimeric protein complex that is conserved across species and is composed of 4 core subunits (*SMC1A*, *SMC3*, *RAD21*, and *STAG* proteins) together with a number of regulatory proteins such as *NIPBL*, *PDS5*, or *ESCO* proteins.<sup>34</sup> The 4 subunits form a ring structure that regulates chromosome segregation during meiosis and mitosis, but recent data suggest additional functions such as double-stranded DNA repair and regulation of transcription.<sup>42,45</sup> In a previous study by Thol et al, recurrent cohesin mutations have been reported in about 6% of AML patients.<sup>45</sup> However, cohesin mutations concerned less than 2% of CBF AML in this study. Interestingly, it has been shown that the cohesin complex could functionally interact with Polycomb

group proteins to control gene transcription.<sup>46</sup> It is an interesting observation that *ASXL* gene mutations<sup>47</sup> as well as cohesin gene mutations<sup>48</sup> are enriched in patients with *RUNX1*-mutated AML. Recently, several experiments have linked cohesin and *RUNX1* in hematopoiesis and leukemogenesis. Notably, *runx* genes expression has been showed to be dependent of *rad21* expression in a zebrafish model.<sup>49</sup> Kon et al showed that forced expression of wild-type *RAD21* in the Kasumi-1 cell line (carrying both t(8;21) and *RAD21* mutation p.K330PfsX6) induced significant growth suppression.<sup>34</sup> Moreover, haploinsufficiency of cohesin proteins appears to be associated with myeloid transformation and aberrant self-renewal linked with broad changes in chromatin occupancy.<sup>50,51</sup> Indeed, Mazumdar et al showed that cohesin mutations led to a state of elevated chromatin accessibility and higher binding at *RUNX1* binding sites.<sup>50</sup> These findings suggest links between alterations in chromatin structure, mediated by cohesin or chromatin modifiers mutations, and cooperativity with the *RUNX1*-*RUNX1* fusion oncoprotein.

In our cohort, 18% of t(8;21) AML patients have mutations involving the cohesin member and 42% of t(8;21) AML patients have mutations involving chromatin modifiers. Overall, 52% of t(8;21) AML patients have at least 1 mutation in 1 of these 2 groups of genes. These findings suggest an important pathway that is specific to t(8;21) AML leukemogenesis and may have biological and clinical significance. Accordingly, transcriptome profiling supports the notion that t(8;21) and inv(16) AML are characterized by different genetic programs.<sup>18</sup> It is likely that future studies focused on the molecular basis of shared pathways as well as pathways specific to the 2 CBF AML subtypes may guide the development of new treatment approaches. Patients with t(8;21) AML who had at least 1 TK pathway mutation associated with at least 1 mutation in a chromatin modifier or cohesin gene had the worst prognosis, which could indicate synergic cooperation between these events. Finally, evaluation of drugs targeting these pathways and translational research integrating these molecular findings with clinical trials will likely improve the treatment of patients with CBF AML.

## Acknowledgments

The authors thank Lamya Haddaoui (Tumour Bank for the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang, N° BB-033-00073, Hôpital Cochin, Paris) and Christophe Roumier and Olivier Nibourel (Tumour Bank for the Acute Leukemia French Association certification NF 96900-2014/65453-1, Centre Hospitalier Régional Universitaire Lille) for handling, conditioning, and storing patient samples. The work of all clinical research assistants is also acknowledged.

This work was supported by the French National Cancer Institute (PRT-K 2010-285 and PRT-K 2012-043).

## Authorship

Contribution: E.J. was the principal investigator of the Core Binding Factor 2006 study; G.L. was the principal investigator of the Treating Patients with Childhood Acute Myeloid Leukemia with Interleukin-2 study; H.D., H.L., and C.P. created the patient database; K.C.-L. and C.R. ensured data management; N.B. performed statistical analysis; E.J., N.B., J.-B.M., N.I., H.D., G.L., and A.P. enrolled patients in the studies; N.D., A.M.-R., M.B., S.G., A.R., M.F., C.P., C.L.,

P.C., and H.L. performed genetic analysis and analyzed mutational data; N.D. and C.P. performed the research and wrote the paper; and C.P., O.A.-W., and J.-B.M. revised the manuscript which was approved by all the authors.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Claude Preudhomme, Laboratory of Hematology, Biology and Pathology Center, Lille University Hospital, Professor J. Leclercq Blvd, 59037 Lille Cedex, France; e-mail: claude.preudhomme@chru-lille.fr.

## References

- Schoch C, Kern W, Schnittger S, Büchner T, Hiddemann W, Haferlach T. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. *Haematologica*. 2004;89(9):1082-1090.
- Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood*. 2010;115(3):453-474.
- Jourdan E, Boissel N, Chevret S, et al; French AML Intergroup. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. *Blood*. 2013;121(12):2213-2223.
- Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. *J Clin Oncol*. 2004;22(18):3741-3750.
- Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. *Br J Haematol*. 2006;135(2):165-173.
- Marcucci G, Mrózek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. *J Clin Oncol*. 2005;23(24):5705-5717.
- Rowley JD. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. *Ann Genet*. 1973;16(2):109-112.
- Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. *N Engl J Med*. 1983;309(11):630-636.
- Renneville A, Roumier C, Biggio V, et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. *Leukemia*. 2008;22(5):915-931.
- Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. *Nat Rev Cancer*. 2002;2(7):502-513.
- Downing JR. The core-binding factor leukemias: lessons learned from murine models. *Curr Opin Genet Dev*. 2003;13(1):48-54.
- Miyamoto T, Nagafuji K, Akashi K, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. *Blood*. 1996;87(11):4789-4796.
- Wiemels JL, Xiao Z, Buffler PA, et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. *Blood*. 2002;99(10):3801-3805.
- Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. *Semin Hematol*. 2002;39(4 Suppl 3):6-11.
- Duployez N, Willekens C, Marceau-Renaud A, Boudry-Labis E, Preudhomme C. Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. *Expert Rev Hematol*. 2015;8(1):43-56.
- Sangle NA, Perkins SL. Core-binding factor acute myeloid leukemia. *Arch Pathol Lab Med*. 2011;135(11):1504-1509.
- Schoch C, Kohlmann A, Schnittger S, et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. *Proc Natl Acad Sci USA*. 2002;99(15):10008-10013.
- Hsu C-H, Nguyen C, Yan C, et al. Transcriptome profiling of pediatric core binding factor AML. *PLoS One*. 2015;10(9):e0138782.
- Micol J-B, Duployez N, Boissel N, et al. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. *Blood*. 2014;124(9):1445-1449.
- Duployez N, Micol J-B, Boissel N, et al. Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21). *Leuk Lymphoma*. 2015;57(1):199-200.
- Metzeler KH. ASXL genes and RUNX1: an intimate connection? *Blood*. 2014;124(9):1382-1383.
- Bendl J, Stourac J, Salanda O, et al. PredictSNP: robust and accurate consensus classifier for prediction of disease-related mutations. *PLOS Comput Biol*. 2014;10(1):e1003440.
- Boissel N, Leroy H, Brethon B, et al; Acute Leukemia French Association (ALFA); Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). *Leukemia*. 2006;20(6):965-970.
- Lausen B, Schumacher M. Maximally selected rank statistics. *Biometrics*. 1992;48(1):73-85.
- Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. *Biometrika*. 1994;81(3):515-526.
- Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med*. 2013;368(22):2059-2074.
- Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. *Blood*. 2010;115(12):2372-2379.
- Bodemer C, Hermine O, Palmérini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. *J Invest Dermatol*. 2010;130(3):804-815.
- Kinoshita K, Hirota S, Isozaki K, et al. Characterization of tyrosine kinase I domain c-kit gene mutation Asn655Lys newly found in primary jejunal gastrointestinal stromal tumor. *Am J Gastroenterol*. 2007;102(5):1134-1136.
- Paschka P, Du J, Schlenk RF, et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AML-SG). *Blood*. 2013;121(1):170-177.
- Dunbar AJ, Gondek LP, O'Keefe CL, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. *Cancer Res*. 2008;68(24):10349-10357.
- Wu H, Zeng H, Dong A, et al. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations. *PLoS One*. 2013;8(12):e83737.
- Gröschel S, Sanders MA, Hoogenboezem R, et al. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. *Blood*. 2015;125(1):133-139.
- Kon A, Shih L-Y, Minamino M, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. *Nat Genet*. 2013;45(10):1232-1237.
- Conway O'Brien E, Prideaux S, Chevassut T. The epigenetic landscape of acute myeloid leukemia. *Adv Hematol*. 2014;2014:1-15.
- Krauth M-T, Eder C, Alpermann T, et al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. *Leukemia*. 2014;28(7):1449-1458.
- Allen C, Hills RK, Lamb K, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. *Leukemia*. 2013;27(9):1891-1901.
- Jones D, Yao H, Romans A, et al. Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. *Genes Chromosomes Cancer*. 2010;49(2):182-191.
- Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. *Blood*. 2007;110(4):1262-1270.
- Mead AJ, Gale RE, Hills RK, et al. Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. *Blood*. 2008;112(2):444-445, author reply 445.



41. Sood R, Hansen NF, Donovan FX, et al. Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia. *Leukemia*. 2016;30(2):501-504.
42. Daou S, Hammond-Martel I, Mashtalir N, et al. The BAP1/ASXL2 histone H2A deubiquitinase complex regulates cell proliferation and is disrupted in cancer. *J Biol Chem*. 2015;290(48):28643-28663.
43. Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. *Blood*. 2013;121(18):3563-3572.
44. Yamamoto Y, Abe A, Emi N. Clarifying the impact of polycomb complex component disruption in human cancers. *Mol Cancer Res*. 2014;12(4):479-484.
45. Thol F, Bollin R, Gehlhaar M, et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. *Blood*. 2014;123(6):914-920.
46. Schaaf CA, Misulovin Z, Gause M, et al. Cohesin and polycomb proteins functionally interact to control transcription at silenced and active genes. *PLoS Genet*. 2013;9(6):e1003560.
47. Chou W-C, Huang H-H, Hou H-A, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. *Blood*. 2010;116(20):4086-4094.
48. Thota S, Viny AD, Makishima H, et al. Genetic alterations of the cohesin complex genes in myeloid malignancies. *Blood*. 2014;124(11):1790-1798.
49. Horsfield JA, Anagnostou SH, Hu JK-H, et al. Cohesin-dependent regulation of Runx genes. *Development*. 2007;134(14):2639-2649.
50. Mazumdar C, Shen Y, Xavy S, et al. Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation. *Cell Stem Cell*. 2015;17(6):675-688.
51. Williams MS, Somerville TCP. Leukemogenic activity of cohesin rings true. *Cell Stem Cell*. 2015;17(6):642-644.